Sino Biopharmaceutical Limited (SBMFF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Wan Chai, Hong Kong. Der aktuelle CEO ist S. Y. Tse.
SBMFF hat IPO-Datum 2010-02-22, 24,379 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $13.58B.
Sino Biopharmaceutical Limited is a Hong Kong-incorporated research and development pharmaceutical conglomerate operating in China since 2000. The company develops and commercializes a diverse portfolio of pharmaceuticals across multiple therapeutic areas, including oncology, cardio-cerebral vascular, hepatitis, orthopedic, and respiratory medicines, as well as innovative chemical pharmaceuticals and parenteral nutritional products. Beyond pharmaceutical manufacturing, Sino Biopharmaceutical operates an integrated healthcare ecosystem comprising hospital operations, optometry services, health food production, pharmaceutical distribution, and medical technology consulting. The company organizes its operations through three main segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others, generating revenue from drug sales, healthcare services, and strategic investments.
